- Home
- AEVA vs CSTL Comparison
AEVA vs CSTL Comparison
Compare AEVA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- CSTL
- Stock Information
- Founded
- AEVA 2019
- CSTL 2007
- Country
- AEVA United States
- CSTL United States
- Employees
- AEVA N/A
- CSTL N/A
- Industry
- AEVA Auto Parts:O.E.M.
- CSTL Medical Specialities
- Sector
- AEVA Consumer Discretionary
- CSTL Health Care
- Exchange
- AEVA Nasdaq
- CSTL Nasdaq
- Market Cap
- AEVA 560.5M
- CSTL 456.2M
- IPO Year
- AEVA N/A
- CSTL 2019
- Fundamental
- Price
- AEVA $17.12
- CSTL $16.29
- Analyst Decision
- AEVA Buy
- CSTL Strong Buy
- Analyst Count
- AEVA 6
- CSTL 6
- Target Price
- AEVA $13.60
- CSTL $37.67
- AVG Volume (30 Days)
- AEVA 2.8M
- CSTL 527.3K
- Earning Date
- AEVA 05-14-2025
- CSTL 05-05-2025
- Dividend Yield
- AEVA N/A
- CSTL N/A
- EPS Growth
- AEVA N/A
- CSTL N/A
- EPS
- AEVA N/A
- CSTL N/A
- Revenue
- AEVA $10,326,000.00
- CSTL $347,083,000.00
- Revenue This Year
- AEVA $80.29
- CSTL N/A
- Revenue Next Year
- AEVA $196.79
- CSTL $1.80
- P/E Ratio
- AEVA N/A
- CSTL N/A
- Revenue Growth
- AEVA 95.90
- CSTL 38.43
- 52 Week Low
- AEVA $2.20
- CSTL $15.45
- 52 Week High
- AEVA $18.74
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- AEVA 69.03
- CSTL 34.64
- Support Level
- AEVA $13.74
- CSTL $15.62
- Resistance Level
- AEVA $18.69
- CSTL $16.43
- Average True Range (ATR)
- AEVA 1.85
- CSTL 0.57
- MACD
- AEVA 0.09
- CSTL 0.07
- Stochastic Oscillator
- AEVA 80.02
- CSTL 24.77
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.